Sepsis Clinical Trial
— DISPLAYOfficial title:
Discover the Immune Signature of Sepsis Caused by Acute Pulmonary Infection: A Cohort Study
Verified date | November 2022 |
Source | Capital Medical University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The goal of this observational study is to describe the immune signature of acute pulmonary infection.The main questions it aims to answer are: 1. Nasal mucosal immune response in patients with influenza infection 2. Difference of immune response between Viral sepsis and Bacterial sepsis 3. Immunological differences between Viral sepsis and Viral pneumonia
Status | Not yet recruiting |
Enrollment | 1000 |
Est. completion date | September 10, 2025 |
Est. primary completion date | April 10, 2025 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Age =18 years at time of signing Informed Consent Form 2. chest imaging confirmed pneumonia. 3. Informed consent is obtained 4. The pneumonia onset =8 days Exclusion Criteria: 1. SaO2/SPO2=94% on room air or Pa02/Fi02 ratio <300mgHg before the onset of pneumonia 2. Severe liver disease (e.g. Child Pugh score = C, AST>5 times upper limit) 3. Patients with known severe renal impairment (estimated glomerular filtration rate =30 mL/min/1.73 m2) or receiving continuous renal replacement therapy, hemodialysis,peritoneal dialysis) 4. Pregnant Or Lactating Women 5. Patients were eligible for organ transplantation or had undergone previous organ transplantation surgery 6. HIV infection 7. Had unstable angina or myocardial infarction within 30 days without vascular recanalization treatment |
Country | Name | City | State |
---|---|---|---|
China | China-Japan Friendship Hospital | Beijing | Beijing |
Lead Sponsor | Collaborator |
---|---|
Capital Medical University |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | upper respiratory infection or pneumonia or Sepsis | Patients were grouped and compared according to their diagnosis. | up to 28 days | |
Secondary | Clinical status | assessed by Sequential Organ Failure Assessment | days 0, 3, 7 | |
Secondary | All cause mortality | up to 28 days | ||
Secondary | Length of hospital stay (days) | up to 28 days | ||
Secondary | Length of ICU stay (days) | up to 28 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05095324 -
The Biomarker Prediction Model of Septic Risk in Infected Patients
|
||
Completed |
NCT02714595 -
Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens
|
Phase 3 | |
Completed |
NCT03644030 -
Phase Angle, Lean Body Mass Index and Tissue Edema and Immediate Outcome of Cardiac Surgery Patients
|
||
Completed |
NCT02867267 -
The Efficacy and Safety of Ta1 for Sepsis
|
Phase 3 | |
Completed |
NCT04804306 -
Sepsis Post Market Clinical Utility Simple Endpoint Study - HUMC
|
||
Recruiting |
NCT05578196 -
Fecal Microbial Transplantation in Critically Ill Patients With Severe Infections.
|
N/A | |
Terminated |
NCT04117568 -
The Role of Emergency Neutrophils and Glycans in Postoperative and Septic Patients
|
||
Completed |
NCT03550794 -
Thiamine as a Renal Protective Agent in Septic Shock
|
Phase 2 | |
Completed |
NCT04332861 -
Evaluation of Infection in Obstructing Urolithiasis
|
||
Completed |
NCT04227652 -
Control of Fever in Septic Patients
|
N/A | |
Enrolling by invitation |
NCT05052203 -
Researching the Effects of Sepsis on Quality Of Life, Vitality, Epigenome and Gene Expression During RecoverY From Sepsis
|
||
Terminated |
NCT03335124 -
The Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock
|
Phase 4 | |
Recruiting |
NCT04005001 -
Machine Learning Sepsis Alert Notification Using Clinical Data
|
Phase 2 | |
Completed |
NCT03258684 -
Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Sepsis and Septic Shock
|
N/A | |
Recruiting |
NCT05217836 -
Iron Metabolism Disorders in Patients With Sepsis or Septic Shock.
|
||
Completed |
NCT05018546 -
Safety and Efficacy of Different Irrigation System in Retrograde Intrarenal Surgery
|
N/A | |
Completed |
NCT03295825 -
Heparin Binding Protein in Early Sepsis Diagnosis
|
N/A | |
Not yet recruiting |
NCT06045130 -
PUFAs in Preterm Infants
|
||
Not yet recruiting |
NCT05361135 -
18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in S. Aureus Bacteraemia
|
N/A | |
Not yet recruiting |
NCT05443854 -
Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01)
|
Phase 3 |